DAXOR CORP
About DAXOR CORP
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2011
- $1.4M
- Net income
- -$7.2M
- Total assets
- $85.7M
- Market cap
- $61.9M
- Gross margin
- 54.9%
- Operating margin
- -400.1%
- Net margin
- -496.8%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $1.4M
- Cost of revenue
- $652.5K
- Gross profit
- $793.8K
- Operating expenses
- $6.6M
- Operating income
- -$5.8M
- Income tax
- -$5.1M
- Net income
- -$7.2M
Balance sheet
- Total assets
- $85.7M
- Current assets
- $81.7M
- Total liabilities
- $49.5M
- Current liabilities
- $49.3M
- Shareholders’ equity
- $36.2M
Cash flow
- Operating cash flow
- -$6.5M
- Investing cash flow
- -$11.4M
- Financing cash flow
- $17.9M
- Net cash flow
- $1.9K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $61.9M
- Dividend yield
- 0.3%
- Shares outstanding
- 6.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 25, 1983
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $7.2M in FY2011.
- Gross margin of 54.9%, net margin -496.8%.
- Trading 32% below its 52-week high.
- Pays a dividend yielding about 0.3% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review DAXOR CORP.
Write a review
News about DAXOR CORP
News & sentiment via Polygon.io
